Home › Research › Caregiving
Neurotransmitter deficits from frontotemporal lobar degeneration
Murley AG, Rowe JB.. Brain : a journal of neurology, 2018-05-01
Topic: Brain proteins, microglia and lab models
Frontotemporal lobar degeneration causes a spectrum of complex degenerative disorders including frontotemporal dementia, progressive supranuclear palsy and corticobasal syndrome, each of which is associated with changes in the principal neurotransmitter systems. We review the evidence for these neurochemical changes and propose that they contribute to symptomatology of frontotemporal lobar degeneration, over and above neuronal loss and atrophy. Despite the development of disease-modifying therapies, aiming to slow neuropathological progression, it remains important to advance symptomatic treatments to reduce the disease burden and improve patients' and carers' quality of life. We propose that targeting the selective deficiencies in neurotransmitter systems, including dopamine, noradrenaline, serotonin, acetylcholine, glutamate and gamma-aminobutyric acid is an important strategy towards this goal. We summarize the current evidence-base for pharmacological treatments and suggest strategies to improve the development of new, effective pharmacological treatments.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Murley, A. G., & Rowe, J. B. (2018). Neurotransmitter deficits from frontotemporal lobar degeneration. Brain : a journal of neurology. https://doi.org/10.1093/brain/awx327
Vancouver
Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain : a journal of neurology. 2018. doi:10.1093/brain/awx327. PMID: 29373632.
BibTeX
@article{murley2018-29373632,
author = {Murley, A. G. and Rowe, J. B.},
title = {{Neurotransmitter deficits from frontotemporal lobar degeneration}},
journal = {Brain : a journal of neurology},
year = {2018},
doi = {10.1093/brain/awx327},
pmid = {29373632},
url = {https://doi.org/10.1093/brain/awx327}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Frontotemporal lobar degeneration causes a spectrum of complex degenerative disorders including frontotemporal dementia, progressive supranuclear palsy and corticobasal syndrome, each of which is associated with changes in the principal neurotransmitter systems.
Why it matters
This review proposes that changes in neurotransmitter systems including dopamine, noradrenaline, serotonin, acetylcholine, glutamate, and gamma-aminobutyric acid contribute to symptoms of frontotemporal lobar degeneration beyond neuronal loss and atrophy. It argues that targeting these selective deficiencies is an important strategy to reduce disease burden and improve quality of life, while disease-modifying therapies aiming to slow neuropathological progression are developed.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Evidence strengthLow
How this study scored 56/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | 4 / 4 | Brain: journal h-index 503 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 208 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 20.8 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 4 / 6 | Cited 10.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 13 other studies in this library |
| Still being cited | 3 / 4 | Cited 72 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author James Benedict Rowe: h-index 101 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Cambridge: institution h-index 1,973 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29373632) |
| Free to read | 2 / 2 | Free to read |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Caregiving
Also tagged “bodies”
1,017 studies in the library carry the topic tag “bodies”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.